TG Therapeutics Looks To Market Ublituximab On Convenience, Pricing In MS

 
• By Alaric DeArment

The drug enters the increasingly competitive space of CD20-targeting therapies for multiple sclerosis, with two agents already approved.

Multiple Sclerosis
TG announces strong top-line Phase III data for ublituximab in multiple sclerosis. • Source: Shutterstock

More from Immunological

More from Therapy Areas